top of page

Infective endocarditis
(Last updated 25 May 2025)

Prevention of infective endocarditis
  • Maintain proper dental and skin hygiene.

  • Be cautious about infections.

  • Avoid self-prescribing antibiotics.

  • In my opinion, do not eat undercooked pork. S. suis IE is common in Thailand. : (

Infective endocarditis prophylaxis

Procedure

Class I

Antibiotic prophylaxis is recommended in dental extractions, oral surgery procedures, and procedures requiring manipulation of the gingival or periapical region of the teeth.

Class IIb

Systemic antibiotic prophylaxis may be considered for high-risk patients undergoing an invasive diagnostic or therapeutic procedure of the respiratory, gastrointestinal, genitourinary tract, skin, or musculoskeletal systems.

peridental procedure
gastrointestinal, urinary tract, musculoskeletal

Patient's Risk

Class I

Previous IE

Surgically implanted prosthetic valves and with any material used for surgical cardiac valve repair.

Transcatheter implanted aortic and pulmonary valvular prostheses.

Untreated cyanotic CHD, and patients treated with surgery or transcatheter procedures with post-operative palliative shunts, conduits, or other prostheses.

After surgical repair, in the absence of residual defects or valve prostheses, antibiotic prophylaxis is recommended only for the first 6 months after the procedure.

VAD

Class IIa

Transcatheter valve repair 

Class IIb

Post heart transplant 

Prophylactic antibiotic regime

No Allergy to penicillin or ampicillin

   

      Amoxicillin                      2 g orally                   50 mg/kg orally up to 2 g

      Ampicillin                        2 g i.m. or i.v.            50 mg/kg i.m or i.v. up to 2 g

      Cefazolin/Ceftriaxone     1 g i.m. or i.v.            50 mg/kg i.m or i.v. up to 2 g

Allergy to penicillin or ampicillin

      Cephalexin                      2 g orally                   50 mg/kg orally up to 2 g

      Azithromycin or

      Clarithromycin                 500 mg orally            15 mg/kg orally up to 500 mg

      Doxycycline                    100 mg orally             <45 kg, 2.2 mg/kg orally

                                                                                >45 kg, 100 mg orally

      Cefazolin or                     1 g i.m. or i.v.              50 mg/kg i.v. or i.m. up to 1 g

      Ceftriaxone

I. DEFINITE ENDOCARDITIS

 

A. Pathologic Criteria

 

     (1) Microorganisms identified in the context of clinical signs of active endocarditis in a vegetation; from cardiac tissue; from an explanted prosthetic valve or sewing ring; from an ascending aortic graft (with concomitant evidence of valve involvement); from an endovascular intracardiac implantable electronic device (CIED); or from an arterial embolus or

     (2) Active endocarditis (may be acute or subacute/chronic ) identified in or on a vegetation; from cardiac tissue; from an explanted prosthetic valve or sewing ring; from an ascending aortic graft (with concomitant evidence of valve involvement); from a CIED; or from an arterial embolus

 

B. Clinical Criteria

 

     (1) 2 Major Criteria

                 or

     (2) 1 Major Criterion and 3 Minor Criteria

                 or

     (3) 5 Minor Criteria

 

II. POSSIBLE ENDOCARDITIS

 

        A. 1 Major Criterion And 1 Minor Criterion

                 or

        B. 3 Minor Criteria

 

III. REJECTED ENDOCARDITIS

 

         A. Firm alternate diagnosis explaining signs/symptoms or

         B. Lack of recurrence despite antibiotic therapy for less than 4 d. or

         C. No pathologic or macroscopic evidence of IE at surgery or autopsy, with antibiotic therapy for less than 4 d or

         D. Does not meet criteria for possible IE, as above

Definitions of Infective Endocarditis According to the 2023 Duke-International Society for Cardiovascular Infectious Diseases Infective Endocarditis (IE) Criteria

I. MAJOR CRITERIA

 

A. Microbiologic Major Criteria

 

(1) Positive blood cultures

i. Microorganisms that commonly cause IE isolated from 2 or more separate blood culture sets (Typical) or

ii. Microorganisms that occasionally or rarely cause IE isolated from 3 or more separate blood culture sets (Nontypical) 

 

(2) Positive laboratory tests

i. Positive polymerase chain reaction (PCR) or other nucleic acid-based technique for Coxiella burnetii, Bartonella species, or Tropheryma whipplei from blood or

ii. Coxiella burnetii antiphase I immunoglobulin G (IgG) antibody titer >1:800 , or isolated from a single blood culture or

iii. Indirect immunofluorescence assays (IFA) for detection of IgM and IgG antibodies to Bartonella henselae or Bartonella quintana with immunoglobulin G (IgG) titer ≥1:800

 

B. Imaging Major Criteria

 

(1) Echocardiography and cardiac computed tomography (CT) imaging

 

i. Echocardiography and/or cardiac CT showing vegetation,e valvular/leaflet perforation,f valvular/leaflet aneurysm, abscess, pseudoaneurysm, or intracardiac fistula or

ii. Significant new valvular regurgitation on echocardiography as compared with previous imaging. Worsening or changing of preexisting regurgitation is not sufficient. or

iii. New partial dehiscence of prosthetic valve as compared with previous imaging 

 

(2) Positron emission computed tomography with 18F-fluorodeoxyglucose ([18F]FDG PET/CT imaging) Abnormal metabolic activity involving a native or prosthetic valve, ascending aortic graft (with concomitant evidence of valve involvement), intracardiac device leads or other prosthetic material

 

C. Surgical Major Criteria

 

Evidence of IE documented by direct inspection during heart surgery neither Major Imaging Criteria nor subsequent histologic or microbiologic confirmation

 

II. MINOR CRITERIA

 

A. Predisposition – Previous history of IE – Prosthetic valve – Previous valve repair – Congenital heart disease – More than mild regurgitation or stenosis of any etiology – Endovascular intracardiac implantable electronic device (CIED) – Hypertrophic obstructive cardiomyopathy – Injection drug use

 

B. Fever Documented temperature greater than 38.0 °C (100.4 °F)

 

C. Vascular Phenomena Clinical or radiological evidence of arterial emboli, septic pulmonary infarcts, cerebral or splenic abscess, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, Janeway lesions, purulent purpura

 

D. Immunologic Phenomena Positive rheumatoid factor, Osler nodes, Roth spots, or immune complex-mediated glomerulonephritis

 

E. Microbiologic Evidence, Falling Short of a Major Criterion

 

1) Positive blood cultures for a microorganism consistent with IE but not meeting the requirements for Major Criterion or

2) Positive culture, PCR, or other nucleic acid based test (amplicon or shotgun sequencing, in situ hybridization) for an organism consistent with IE from a sterile body site other than cardiac tissue, cardiac prosthesis, or arterial embolus; or a single finding of a skin bacterium by PCR on a valve or wire without additional clinical or microbiological supporting evidence 

 

F. Imaging Criteria Abnormal metabolic activity as detected by [18F]FDG PET/CT within 3 mo of implantation of prosthetic valve, ascending aortic graft (with concomitant evidence of valve involvement), intracardiac device leads or other prosthetic material

G. Physical Examination Criteria New valvular regurgitation identified on auscultation if echocardiography is not available. Worsening or changing of preexisting murmur not sufficient

Typical organism

Staphylococcus aureus; Staphylococcus lugdunensis; Enterococcus faecalis

all streptococcal species (except for Streptococcus pneumoniae and Streptococcus pyogenes),

 

Granulicatella and Abiotrophia spp., Gemella spp., HACEK group microorganisms (Haemophilus species, Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae).

 

In the setting of intracardiac prosthetic material, the following additional bacteria should be included as “typical” pathogens:

 

coagulase negative staphylococci, Corynebacterium striatum and Corynebacterium jeikeium, Serratia marcescens, Pseudomonas aeruginosa, Cutibacterium acnes, nontuberculous mycobacteria (especially M. chimaerae), and Candida spp.

Oral antibiotic treatment

The POET trial: ​A randomized, non-inferiority trial involving 400 stable adults with left-sided endocarditis assessed the effectiveness of switching from intravenous antibiotics (199 patients) to oral antibiotics (201 patients). All patients initially received at least ten days of intravenous treatment before the switch to outpatient care for the oral group.

 

The primary outcome measured was a composite of all-cause mortality, unplanned cardiac surgery, embolic events, or relapse of bacteremia within six months. The median treatment duration was 19 days for the intravenous group and 17 days for the oral group (P=0.48). The primary composite outcome occurred in 24 patients (12.1%) in the intravenous group and 18 patients (9.0%) in the oral group, indicating a difference of 3.1 percentage points (95% CI: -3.4 to 9.6; P=0.40). 

 

This finding showed that oral treatment was non-inferior to continued intravenous treatment in stable patients with left-sided endocarditis.

Eligibility Criteria for Starting Oral Antibiotics from the POET Trial:

- Blood culture: S. aureus, Streptococci, CONS or E. faecalis

- No fever for> 2 days

- WBC < 15,000 /μL

- CRP < 25% of max measured value or < 20 mg/L

- Treated with relevant i.v. antibiotics ≥ 10 days and ≥ 7 days after valve surgery

- BMI ≤ 40 kg/m^2 and no malabsorption

- No new surgical indication

- Able to follow up OPD clinic 2-3 times/week, and perform TOE to confirm sufficient response to treatment

Oral regimens recommended in the POET trial (Supplementary Appendix)

Penicillin and methicillin-sensitive Staphylococcus aureus and coagulase-negative staphylococci:

1) Amoxicillin 1 g x 4 and fusidic acid 0.75 g x 2

2) Amoxicillin 1 g x 4 and rifampicin 0.6 g x 2

3) Linezolid 0.6 g x 2 and fusidic acid 0.75 g x 2

4) Linezolid 0.6 g x 2 and rifampicin 0.6 g x 2

Methicillin-sensitive Staphylococcus aureus and coagulase-negative staphylococci

1) Dicloxacillin 1 g x 4 and fusidic acid 0.75 g x 2

2) Dicloxacillin 1 g x 4 and rifampicin 0.6 g x 2

3) Linezolid 0.6 g x 2 and fucidic acid 0.75g x 2

4) Linezolid 0.6 g x 2 and rifampicin 0.6 g x 2

Methicillin-resistant coagulase-negative staphylococci

1) Linezolid 0.6 g x 2 and fusidic acid

2) Linezolid 0.6 g x 2 and rifampicin 0.6 g x2

Enterococcus faecalis:

1) Amoxicillin 1 g x 4 and rifampicin 0.6 g x 2

2) Amoxicillin 1 g x 4 and moxifloxacin 0.4 g x 1

3) Linezolid 0.6 g x 2 and rifampicin 0.6 g x 2

4) Linezolid 0.6 g x 2 and moxifloxacin 0.4 g x 1

Streptococci with a minimal inhibitory concentration for penicillin of <1 mg/L:

1) Amoxicillin 1 g x 4 and rifampicin 0.6 g x 2

2) Linezolid 0.6 g x 2 and rifampicin 0.6 g x 2

3) Linezolid 0.6 g x 2 and moxifloxacin 0.4 g x1

Streptococci with a minimal inhibitory concentration for penicillin of ≥1 mg/L:

1) Linezolid 0,6 g x2 and rifampicin 0.6 g x 2

2) Moxifloxacin 0.4 g x 1 and rifampicin 0.6 g x 2

3) Moxifloxacin 0.4 g x 1 and clindamycin 06 g x3

References

1) Victoria Delgado, Nina Ajmone Marsan, Suzanne de Waha, Nikolaos Bonaros, Margarita Brida, Haran Burri, Stefano Caselli, Torsten Doenst, Stephane Ederhy, Paola Anna Erba, Dan Foldager, Emil L Fosbøl, Jan Kovac, Carlos A Mestres, Owen I Miller, Jose M Miro, Michal Pazdernik, Maria Nazarena Pizzi, Eduard Quintana, Trine Bernholdt Rasmussen, Arsen D Ristić, Josep Rodés-Cabau, Alessandro Sionis, Liesl Joanna Zühlke, Michael A Borger, ESC Scientific Document Group , 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM), European Heart Journal, Volume 44, Issue 39, 14 October 2023, Pages 3948–4042, https://doi.org/10.1093/eurheartj/ehad193

2) Fowler VG, Durack DT, Selton-Suty C, Athan E, Bayer AS, Chamis AL, Dahl A, DiBernardo L, Durante-Mangoni E, Duval X, Fortes CQ, Fosbøl E, Hannan MM, Hasse B, Hoen B, Karchmer AW, Mestres CA, Petti CA, Pizzi MN, Preston SD, Roque A, Vandenesch F, van der Meer JTM, van der Vaart TW, Miro JM. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria. Clin Infect Dis. 2023 Aug 22;77(4):518-526. doi: 10.1093/cid/ciad271. Erratum in: Clin Infect Dis. 2023 Oct 13;77(8):1222. doi: 10.1093/cid/ciad510. PMID: 37138445; PMCID: PMC10681650.

Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, Bruun NE, Høfsten DE, Fursted K, Christensen JJ, Schultz M, Klein CF, Fosbøll EL, Rosenvinge F, Schønheyder HC, Køber L, Torp-Pedersen C, Helweg-Larsen J, Tønder N, Moser C, Bundgaard H. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med. 2019 Jan 31;380(5):415-424. doi: 10.1056/NEJMoa1808312. Epub 2018 Aug 28. PMID: 30152252.

©2023 BY Piti Niyomsirivanich, MD. (Personal website)

 

Disclaimer

This site is designed to supplement clinical judgment and should be used alongside clinical expertise and the guidelines.

 

We assume no responsibility for how you utilize or interpret or any other information provided on this website.

bottom of page